Boster Immunoleader

antibody

Anti-IGFBP3 Antibody

PA1498

100 ug/vial

200 USD

polyclonal

rabbit

western blot, immunohistochemistry - paraffin section

Anti-IGFBP3 Antibody

PA1498

Polyclonal

Rabbit IgG polyclonal antibody for Insulin-like growth factor-binding protein 3(IGFBP3) detection. Tested with WB, IHC-P in Human.

200 USD

Rabbit IgG

100 ug/vial

Lyophilized

No cross reactivity with other proteins.

Reacts with: human

WB,IHC-P

Concentration: 0.1-0.5μg/ml; Tested Species: Human

Concentration: 0.5-1μg/ml; Tested Species: Human

Tested Species: In-house tested species with positive results. Predicted Species: Species predicted to be fit for the product based on sequence similarities. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.

A synthetic peptide corresponding to a sequence in the middle region of human IGFBP3(182-198aa IKKGHAKDSQRYKVDYE).

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Immunogen affinity purified.

Add 0.2ml of distilled water will yield a concentration of 500ug/ml.

At -20˚C for one year. After reconstitution, at 4˚C for one month. It can also be aliquotted and stored frozen at -20˚C for a longer time. Avoid repeated freezing and thawing.

Boster provides a series of assays reacted with primary antibodies. Antibody can be supported by chemiluminescence kit EK1002 in WB, supported by SA1022 in IHC(P).

IGFBP3, Insulin-like growth fator-binding protein 3, is a member of the insulin-like growth factor binding protein(IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. IGFBP3 is located on chromosome 7. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit(IGFALS) and either insulin-like growth factor(IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized.

1. Lofqvist, C., Chen, J., Connor, K. M., Smith, A. C. H., Aderman, C. M., Liu, N., Pintar, J. E., Ludwig, T., Hellstrom, A., Smith, L. E. H. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth.Proc. Nat. Acad. Sci. 104: 10589-10594, 2007. 2. Nwosu BU, et al. Evidence of insulin-like growth factor binding protein-3 proteolysis during growth hormone stimulation testing. J Pediatr Endocrinol Metab, 2011. 3. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3. Safarinejad MR, et al. Growth Horm IGF Res, 2011 Jun.

IGFBP3

Insulin-like growth factor-binding protein 3(IBP-3/IGF-binding protein 3/IGFBP-3)

insulin-like growth factor binding protein 3

Acid stable subunit of the 140 K IGF complex antibody Binding protein 29 antibody Binding protein 53 antibody BP 53 antibody BP53 antibody Growth hormone dependent binding protein antibody IBP 3 antibody IBP-3 antibody IBP3 antibody IBP3_HUMAN antibody IGF binding protein 3 antibody IGF-binding protein 3 antibody IGFBP 3 antibody IGFBP-3 antibody IGFBP3 antibody Insulin Like Growth Factor Binding Protein 3 antibody Insulin-like growth factor-binding protein 3 antibody

P17936